Mesial Temporal Lobe Epilepsy: Evaluation and Management
Initial Evaluation
For patients with suspected mesial temporal lobe epilepsy (MTLE), proceed with comprehensive presurgical evaluation after failure of 2 appropriately chosen antiepileptic drugs, as this defines drug-resistant epilepsy (DRE) and warrants surgical consideration. 1
Diagnostic Workup
The evaluation must identify the epileptogenic zone through:
Video-EEG monitoring: Essential for capturing seizure semiology and confirming mesial temporal onset. While some studies suggest ambulatory EEG may suffice in highly selected cases with unilateral mesial temporal sclerosis (MTS) and concordant interictal activity 2, this remains controversial with significant inter-rater variability 3. Standard practice requires prolonged video-EEG monitoring for most patients to ensure accurate localization.
High-quality epilepsy-protocol MRI: Critical for identifying MTS, the most common substrate in MTLE. The diagnostic yield doubles when performed by experienced neuroradiologists with knowledge of suspected localization 4. Lesional findings (hippocampal sclerosis, cavernous malformations, glioneuronal tumors) warrant early surgical intervention 4.
Neuropsychological assessment: Evaluates baseline cognitive function and helps predict postoperative outcomes, particularly memory changes.
Additional modalities: PET, SPECT, and electroencephalographic source imaging (ESI) add value when MRI is non-lesional or findings are discordant 5.
Critical Pitfall: Non-Lesional MTLE
In non-lesional MTLE, bilateral invasive evaluation should be strongly considered 6. Up to 50% of non-lesional cases experience surgical failure, and bilateral independent seizure onset is a key reason. Among patients with presumed unilateral non-lesional MTLE, bilateral mesial temporal seizures were confirmed in a significant subset despite unilateral non-invasive data 6.
Surgical Management
Gold Standard: Anterior Temporal Lobectomy (ATL)
ATL remains the gold-standard treatment with proven efficacy in 2 class I trials, achieving seizure freedom rates of 60-80% at 2-year follow-up 1. Selective amygdalohippocampectomy (SAH) offers similar outcomes with potential preservation of lateral temporal neocortex.
Minimally Invasive Alternative: MRgLITT
For patients seeking less invasive options or those refusing open surgery, magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is an evidence-based alternative 1.
MRgLITT Efficacy and Outcomes:
- Seizure freedom rates: 44-78% at 1 year, with meta-analyses reporting 55-58% 1
- 77% of patients achieve significant clinical benefit (freedom or major reduction) 1
- Hospital stay: 1 night versus 3-4 nights for ATL 1
- Lower rates than ATL but superior to continued medical management alone
MRgLITT Safety Profile:
- Most common complication: Visual field deficits (5-7%), typically contralateral superior quadrantanopsia from optic radiation involvement 1
- Clinically significant hemorrhage: <0.5% 1
- No reports of hemiparesis or wound infections 1
- Better preservation of naming, object recognition, and contextual verbal memory compared to open surgery 1
MRgLITT Contraindications 1:
- Inability to identify epileptogenic focus
- MRI contraindications
- Unstable medical conditions, uncontrollable anticoagulation, bleeding disorders
Decision Algorithm
For lesional MTLE with clear unilateral onset:
- Offer choice between ATL (higher seizure freedom) and MRgLITT (lower morbidity, faster recovery)
- Many patients now choose MRgLITT despite slightly lower efficacy 1
For non-lesional MTLE:
- Consider bilateral SEEG evaluation 6
- If bilateral independent seizures confirmed: responsive neurostimulation (RNS) is preferred over resection 6
For patients with bilateral disease or eloquent cortex involvement:
- Neuromodulation (RNS, deep brain stimulation, vagus nerve stimulation) over resection 4
Important Nuance on Long-Term Outcomes
While some data suggest MRgLITT seizure freedom rates may decline over time (64% at 12 months, 47% at 24 months, 42% at 36 months) 1, these represent early experience. Critically, patients with surgically treated DRE show normalized mortality even without complete seizure freedom, as long as seizures with impaired awareness are reduced 1.
Surgical Failure Does Not Preclude Further Options
MRgLITT does not eliminate the possibility of subsequent more extensive ablations or open surgery 1. This makes it a reasonable first-line surgical option for appropriate candidates.
Key Clinical Principle
Surgery remains dramatically underutilized despite proven mortality and quality-of-life benefits 1. Most patients with DRE do not ultimately undergo surgery after referral, but still benefit from comprehensive epilepsy center evaluation including diagnosis verification (one-third have non-epileptic events), etiology clarification, and optimized medical management 4.